- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02386397
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer (BREGO)
Activity of Regorafenib in Combination With Modified Gemcitabine - Oxaliplatin Chemotherapy (mGEMOX) in Patients With Advanced Biliary Tract Cancer (BTC): A Phase Ib-II Trial (BREGO)
Study Overview
Detailed Description
Regorafenib (BAY 73-4506) was assessed in metastatic colorectal cancer in the phase III randomized CORRECT trial. 760 metastatic colorectal cancer patients were recruited after the failure of all standard therapies.
Given the promising efficacy and favorable tolerability profile of mGEMOX and the potential benefits of targeting the VEGF and Ras/Raf pathway, we propose to assess the combination of Regorafenib with mGEMOX in advanced digestive cancer.
This study is to determine the Regorafenib Dose (RD) for the phase II trial of Regorafenib administered in combination with mGEMOX in patients with advanced biliary tract cancer.
The phase I study of Regorafenib in advanced colorectal cancer showed a pronounced interindividual variability of drug exposition. Furthermore, the CORRECT study shows a large pharmacological variability of plasma concentration for Regorafenib and its metabolites. In this study, we propose to explore the pharmacological variability and his potential heritability by the therapeutic drug monitoring of Regorafenib. The objective is to understand and to control the pharmacological variability of Regorafenib and finally to predict the therapeutic response or the toxicity, especially in a population of patients with biliary tract cancer.
In addition, we will complete this study by exploring the gene variants of drug metabolism. The genes are POR (P450 OxidoReductase,) NR1I2 (Nuclear Receptor subfamily 1, group I, member 2) and a part of the regulatory sequences of CYP3A4.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Montpellier, France, 34298
- Centre Val D'Aurelle
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adenocarcinoma of the biliary tract
- Metastatic disease with no curative surgery option or metastatic recurrence after resection.
- Only for phase II: At least one measurable lesion in a non-irradiated area according to Response Evaluation Criteria in Solid Tumors
- No biliary obstruction.
- Age between 18 and 75 years.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Life expectancy higher than 3 months.
- No prior chemotherapy for advanced disease. Previous adjuvant chemotherapy including Gemcitabine and/or platinum based is allowed if completed at least 6 months previously and relapsing after completion of the last dose.
- Total bilirubin ≤ 2.5 times the upper limit of the normal range. Patients with jaundice or evidence of bile duct obstruction, in whom the biliary tree can be decompressed by endoscopic or percutaneous endoprothesis (at least 15 days before inclusion) with subsequent reduction in total bilirubin ≤ 3 ULN, will be eligible for the study.
- Aminotransferases (AST, ALT) ≤ 2.5 ULN (≤ 5 ULN in case of diffuse hepatic involvement), INR < 1.5 (following vitamin K1 injection in patients with current or recent history of jaundice or bile duct obstruction), serum creatinine clearance calculated > 50 mL/min/1.73m² according to the Modification of Diet in Renal Disease (MDRD) formula, neutrophils ≥ 1.5.109/L, platelets ≥ 100.109/L, hemoglobin ≥ 9 g/dL (red blood cell transfusion is allowed if needed).
- Signed informed consent obtained before any study specific procedures.
- Patients must be affiliated to a Social Security System.
Exclusion Criteria:
- Known central nervous system metastases.
- Known history of human immunodeficiency virus (HIV) infection
- Contraindication or history of allergic reaction to one of the treatment components.
- Previous irradiation (external radiotherapy or brachytherapy) within 30 days prior to study treatment.
- Major surgery within 30 days prior to study treatment.
- Participation in another clinical trial within 30 days prior to study treatment.
- Concomitant systemic immunotherapy, chemotherapy, antitumor hormone therapy, targeted therapy or any experimental therapy.
- Active uncontrolled infection, peripheral neuropathy grade ≥ 2, acute or subacute bowel obstruction, history of inflammatory bowel disease, interstitial pneumonitis, respiratory failure, renal failure, dysphagia or any malabsorption condition.
- Symptomatic coronary heart disease or myocardial infarction in the past 6 months, congestive heart failure (NYHA class II), prior cerebrovascular accident.
- Uncontrolled hypertension (systolic blood pressure (BP) > 150 mmHg or diastolic pressure > 90 mmHg despite optimal medical management).
- Proteinuria of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) ≥ grade 2 (i.e. urinary protein ≥ 1.0 g/24 hrs).
- Patients with current or anticipated need for strong Cytochrome P450 3A4 (CYP3A4) inhibitors or inducers.
- Pregnancy (or positive β-HCG dosage at inclusion), breast-feeding, or lack of effective contraception in male or female patients of reproductive potential.
- Other malignancies either currently active or in the last 5 years, except adequately treated in situ carcinoma of the cervix and basal or squamous cell skin carcinoma.
- Legal incapacity or physical, psychological or mental status interfering with the patient's ability to sign the informed consent or to terminate the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Regorafenib: X mg/d, PO, from day 1 to day 14; day 15 to day 20: off-treatment mGEMOX: infusion on days 1 and 8
|
Regorafenib: X mg/d, PO, from day 1 to day 14; day 15 to day 20: off-treatment
Other Names:
mGEMOX: infusion on days 1 and 8: Gemcitabine 900 mg/m² IV in 30 minutes Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine
Other Names:
|
Other: Standard treatment
mGEMOX: infusion on days 1 and 8
|
mGEMOX: infusion on days 1 and 8: Gemcitabine 900 mg/m² IV in 30 minutes Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Limiting toxicity
Time Frame: up to 5 years
|
To assess Limiting Toxicities during and within 6 weeks (2 cycles) after the beginning of the treatment.
|
up to 5 years
|
Collaborators and Investigators
Investigators
- Study Director: DOMERGUE Jacques, Institut régional du Cancer - Val d'Aurelle
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Digestive System Neoplasms
- Biliary Tract Diseases
- Biliary Tract Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gemcitabine
- Oxaliplatin
Other Study ID Numbers
- ICM2013/09
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Digestive Cancer
-
Instituto Mexicano del Seguro SocialCompletedDigestive CancerMexico
-
Centre Antoine LacassagneRecruitingMetastatic or Locally-advanced Digestive CancerFrance
-
GERCOR - Multidisciplinary Oncology Cooperative...Not yet recruiting
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI); Dartmouth-Hitchcock Medical Center; West Virginia... and other collaboratorsActive, not recruitingGynecologic Cancer | Thoracic Cancer | Gastrointestinal Cancer | Other CancerUnited States
-
Hospices Civils de LyonCompletedLung Cancer and Cancer of Digestive SystemFrance
-
RemeGen Co., Ltd.RecruitingDigestive CancerChina
-
Royal Marsden NHS Foundation TrustMerck KGaA, Darmstadt, Germany; 4SC AGUnknownCancer | GI CancerUnited Kingdom
-
Singlera Genomics Inc.Fudan University; Shanghai Zhongshan Hospital; Shanghai Public Health Clinical... and other collaboratorsCompletedHepatocellular Carcinoma | Colorectal Cancer | Esophageal Cancer | Gastric (Stomach) CancerChina
-
Dana-Farber Cancer InstituteRecruitingGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Gastrointestinal CancerUnited States
-
Claus Lindbjerg AndersenUniversity of AarhusRecruitingGastrointestinal Neoplasms | Colonic Diseases | Colorectal Neoplasms | Rectal Diseases | Colorectal Cancer | Rectal Cancer | Rectal Neoplasms | Colonic Neoplasms | Gastrointestinal Cancer | Colo-rectal Cancer | Colonic Cancer | Digestive System Neoplasm | Digestive System Disease | Gastro-Intestinal Disorder | ctDNADenmark
Clinical Trials on Regorafenib
-
Second Affiliated Hospital of Guangzhou Medical...Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Shenzhen... and other collaboratorsActive, not recruitingHepatocellular Carcinoma Non-resectableChina
-
Zhongda HospitalSun Yat-sen University; Jiangsu Cancer Institute & Hospital; Zhejiang University and other collaboratorsNot yet recruitingHepatocellular Carcinoma
-
Spanish Cooperative Group for the Treatment of...BayerCompletedColorectal Neoplasms | Metastatic DiseaseSpain
-
Rennes University HospitalRecruiting
-
Taipei Veterans General Hospital, TaiwanChang Gung Memorial Hospital; Koo Foundation Sun Yat-Sen Cancer CenterCompletedMetastatic Colorectal CancerTaiwan
-
Spanish Cooperative Group for the Treatment of...BayerCompletedStudy Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC (RE-ARRANGE)Metastatic Colorectal CancerSpain
-
Tianjin Medical University Cancer Institute and...Not yet recruitingAdvanced/Metastatic Colorectal CancerChina
-
Gustave Roussy, Cancer Campus, Grand ParisBayerRecruiting
-
Institute of Mother and Child, Warsaw, PolandMaria Sklodowska-Curie National Research Institute of OncologyRecruitingOsteosarcoma | Ewing Sarcoma of BonePoland
-
Massachusetts General HospitalBayerCompletedAcute Myeloid LeukemiaUnited States